In dose escalation, patients with advanced solid tumors were administered ensartinib at doses of 25 to 250 mg once daily, and in dose expansion, patients with advanced ALK-rearranged NSCLC were administered additional doses of 225 mg once daily. This evidence concerns the gene ALK and non-small cell lung carcinoma.